Daniel Bradbury Sells 2,400 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 2,400 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $20.45, for a total value of $49,080.00. Following the completion of the sale, the director now owns 17,944 shares in the company, valued at approximately $366,954.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Daniel Bradbury also recently made the following trade(s):

• On Thursday, April 4th, Daniel Bradbury sold 9,152 shares of Castle Biosciences stock. The stock was sold at an average price of $21.45, for a total value of $196,310.40.
• On Monday, March 4th, Daniel Bradbury sold 23,323 shares of Castle Biosciences stock. The shares were sold at an average price of $20.68, for a total value of $482,319.64.
• On Wednesday, February 7th, Daniel Bradbury sold 2,074 shares of Castle Biosciences stock. The stock was sold at an average price of $23.20, for a total transaction of $48,116.80.

Castle Biosciences Stock Performance

CSTL stock opened at $20.78 on Friday. The firm has a market cap of $570.41 million, a P/E ratio of -9.62 and a beta of 0.93. The firm’s fifty day moving average is $22.06 and its 200 day moving average is $19.73. Castle Biosciences, Inc. has a 52 week low of $9.26 and a 52 week high of $26.70.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.74. The business had revenue of $66.12 million during the quarter, compared to analyst estimates of $51.32 million. Castle Biosciences had a negative net margin of 26.15% and a negative return on equity of 14.92%. As a group, analysts forecast that Castle Biosciences, Inc. will post -2.41 EPS for the current year.

Hedge Funds Weigh In On Castle Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BluePath Capital Management LLC bought a new stake in Castle Biosciences in the third quarter valued at approximately $31,000. Royal Bank of Canada raised its holdings in Castle Biosciences by 40.5% during the 2nd quarter. Royal Bank of Canada now owns 2,880 shares of the company’s stock valued at $39,000 after buying an additional 830 shares during the last quarter. O Dell Group LLC bought a new stake in Castle Biosciences during the 4th quarter valued at $44,000. Tower Research Capital LLC TRC boosted its position in Castle Biosciences by 61.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company’s stock valued at $47,000 after buying an additional 691 shares during the period. Finally, Osaic Holdings Inc. grew its holdings in Castle Biosciences by 37.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,626 shares of the company’s stock worth $50,000 after acquiring an additional 984 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on CSTL. KeyCorp boosted their price target on shares of Castle Biosciences from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday, March 1st. Guggenheim started coverage on shares of Castle Biosciences in a research report on Thursday, December 14th. They issued a “buy” rating and a $25.00 target price for the company. Finally, Scotiabank increased their target price on Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a research note on Friday, March 1st.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.